Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

428 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer.
McHugh D, Eisenberger M, Heath EI, Bruce J, Danila DC, Rathkopf DE, Feldman J, Slovin SF, Anand B, Chu R, Lackey J, Reyno L, Antonarakis ES, Morris MJ. McHugh D, et al. Among authors: antonarakis es. Invest New Drugs. 2019 Oct;37(5):1052-1060. doi: 10.1007/s10637-019-00731-5. Epub 2019 Feb 6. Invest New Drugs. 2019. PMID: 30725389 Free PMC article. Clinical Trial.
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers.
Antonarakis ES, Heath EI, Walczak JR, Nelson WG, Fedor H, De Marzo AM, Zahurak ML, Piantadosi S, Dannenberg AJ, Gurganus RT, Baker SD, Parnes HL, DeWeese TL, Partin AW, Carducci MA. Antonarakis ES, et al. J Clin Oncol. 2009 Oct 20;27(30):4986-93. doi: 10.1200/JCO.2009.21.9410. Epub 2009 Aug 31. J Clin Oncol. 2009. PMID: 19720908 Free PMC article. Clinical Trial.
Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study.
Keizman D, Zahurak M, Sinibaldi V, Carducci M, Denmeade S, Drake C, Pili R, Antonarakis ES, Hudock S, Eisenberger M. Keizman D, et al. Among authors: antonarakis es. Clin Cancer Res. 2010 Nov 1;16(21):5269-76. doi: 10.1158/1078-0432.CCR-10-1928. Epub 2010 Oct 26. Clin Cancer Res. 2010. PMID: 20978144 Free PMC article. Clinical Trial.
Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database.
Antonarakis ES, Chen Y, Elsamanoudi SI, Brassell SA, Da Rocha MV, Eisenberger MA, McLeod DG. Antonarakis ES, et al. BJU Int. 2011 Aug;108(3):378-85. doi: 10.1111/j.1464-410X.2010.09878.x. Epub 2010 Nov 23. BJU Int. 2011. PMID: 21091976 Free PMC article.
The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation.
Keizman D, Huang P, Antonarakis ES, Sinibaldi V, Carducci MA, Denmeade S, Kim JJ, Walczak J, Eisenberger MA. Keizman D, et al. Among authors: antonarakis es. Prostate. 2011 Nov;71(15):1608-15. doi: 10.1002/pros.21377. Epub 2011 Mar 22. Prostate. 2011. PMID: 21432863 Free PMC article.
428 results